Genscript Biotech has been granted a patent for anti-LAG-3 constructs containing single-domain antibodies that specifically target LAG-3. The patent covers methods of creating and utilizing these constructs, offering potential advancements in immunotherapy. GlobalData’s report on Genscript Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Genscript Biotech, was a key innovation area identified from patents. Genscript Biotech's grant share as of May 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-lag-3 construct with single-domain antibody
A recently granted patent (Publication Number: US11958903B2) discloses an innovative anti-lymphocyte activation gene-3 (anti-LAG-3) construct that includes a single-domain antibody (sdAb) specifically targeting LAG-3. The construct comprises various sequences of complimentary-determining regions (CDRs) that recognize LAG-3, providing a detailed framework for the design and development of therapeutic agents targeting this immune checkpoint molecule. The patent also covers the fusion of the sdAb with an Fc fragment, creating a heavy chain-only antibody (HCAb) with specific binding properties and potential applications in cancer treatment.
Furthermore, the patent outlines the incorporation of additional antigen binding portions in the construct, allowing for the specific recognition of other immune checkpoint molecules like PD-1. By fusing the sdAb with different polypeptides and peptide linkers, the construct can target multiple epitopes simultaneously, potentially enhancing its therapeutic efficacy in treating various cancers. The patent also includes a pharmaceutical composition containing the anti-LAG-3 construct and a method for treating cancer, particularly colon cancer, by administering this composition to individuals. Overall, the patent provides a comprehensive framework for the development of novel immunotherapies targeting LAG-3 and other immune checkpoint molecules, offering promising avenues for cancer treatment.
To know more about GlobalData’s detailed insights on Genscript Biotech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
